PTC Therapeutics, Inc. Proceeds from Convertible Debt
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Convertible Debt of $550.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-07-30
- PTC Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2019-12-31 was -$304.00K.
- PTC Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2018-12-31 was $0.00.
- PTC Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2018-09-30 was $0.00.
- PTC Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2017-12-31 was -$40.00M.
- PTC Therapeutics, Inc. proceeds from convertible debt for fiscal 2019 was $279.27M.
- PTC Therapeutics, Inc. proceeds from convertible debt for fiscal 2018 was $0.00.
- PTC Therapeutics, Inc. proceeds from convertible debt for fiscal 2017 was $0.00.
- PTC Therapeutics, Inc. proceeds from convertible debt for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $550.00M 10-Q · filed 2026-07-30 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-10-29 | |||
| 2019-12-31 | -$304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $279.27M 10-K · filed 2022-02-22 | ||
| 2019-09-30 | $279.57M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | |||
| 2017-12-31 | -$40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$40.00M derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $40.00M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $40.00M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $0.00 derived: sum of 2 quarters · filed 2018-03-06 | $0.00 10-K · filed 2018-03-06 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $150.00M 10-K · filed 2018-03-06 | ||
| 2015-09-30 | $150.00M 10-Q · filed 2016-11-03 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |